{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"69.2","upperLimit":"352.5","value":"112.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"T cells CD4+ Ki67; C1D8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-45.8","upperLimit":"57.6","value":"10.3"},{"groupId":"OG001","lowerLimit":"-24.0","upperLimit":"66.7","value":"16.7"},{"groupId":"OG002","lowerLimit":"-43.8","upperLimit":"37.8","value":"-25.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"T cells CD4+ Ki67; C2D1"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"58.0","upperLimit":"925.0","value":"153.1"},{"groupId":"OG002","lowerLimit":"65.1","upperLimit":"215.0","value":"118.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"T cells CD4+ Ki67; C2D8"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"-48.0","upperLimit":"-18.8","value":"-33.4"},{"groupId":"OG002","lowerLimit":"-31.4","upperLimit":"81.3","value":"21.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"T cells CD4+ Ki67; C3D1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-25.0","upperLimit":"88.9","value":"20.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"T cells CD8+ Ki67; C1D8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-70.8","upperLimit":"117.5","value":"-20.0"},{"groupId":"OG001","lowerLimit":"-9.9","upperLimit":"431.3","value":"133.3"},{"groupId":"OG002","lowerLimit":"-67.5","upperLimit":"173.3","value":"-62.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"T cells CD8+ Ki67; C2D1"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"-35.2","upperLimit":"900.0","value":"66.7"},{"groupId":"OG002","lowerLimit":"-57.0","upperLimit":"318.3","value":"-40.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"T cells CD8+ Ki67; C2D8"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"0.0","value":"0.0"},{"groupId":"OG002","lowerLimit":"-73.0","upperLimit":"200.0","value":"-55.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"T cells CD8+ Ki67; C3D1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-20.5","upperLimit":"2.9","value":"-12.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"T cells CD4+; C1D8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-15.2","upperLimit":"26.2","value":"10.1"},{"groupId":"OG001","lowerLimit":"-20.2","upperLimit":"45.7","value":"6.1"},{"groupId":"OG002","lowerLimit":"-16.6","upperLimit":"34.9","value":"9.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"T cells CD4+; C2D1"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"-6.5","upperLimit":"63.8","value":"12.8"},{"groupId":"OG002","lowerLimit":"-13.2","upperLimit":"52.7","value":"16.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"T cells CD4+; C2D8"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"-32.6","upperLimit":"8.0","value":"-12.3"},{"groupId":"OG002","lowerLimit":"6.3","upperLimit":"39.9","value":"23.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"T cells CD4+; C3D1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-37.8","upperLimit":"-10.3","value":"-23.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"T cells CD8+; C1D8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-30.2","upperLimit":"23.1","value":"3.6"},{"groupId":"OG001","lowerLimit":"-18.2","upperLimit":"59.2","value":"40.4"},{"groupId":"OG002","lowerLimit":"-15.6","upperLimit":"50.6","value":"10.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"T cells CD8+; C2D1"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"-14.6","upperLimit":"60.9","value":"30.1"},{"groupId":"OG002","lowerLimit":"-18.0","upperLimit":"71.2","value":"13.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"T cells CD8+; C2D8"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"-24.5","upperLimit":"7.9","value":"-8.3"},{"groupId":"OG002","lowerLimit":"-5.5","upperLimit":"2.6","value":"0.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"T cells CD8+; C3D1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-40.6","upperLimit":"-24.7","value":"-29.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"B cells; C1D8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3.1","upperLimit":"56.9","value":"6.2"},{"groupId":"OG001","lowerLimit":"-1.5","upperLimit":"650.0","value":"27.2"},{"groupId":"OG002","lowerLimit":"-22.0","upperLimit":"128.0","value":"-12.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"B cells; C2D1"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"-4.8","upperLimit":"1543.8","value":"20.6"},{"groupId":"OG002","lowerLimit":"-26.2","upperLimit":"43.1","value":"-8.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"B cells; C2D8"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"-8.6","upperLimit":"3.6","value":"-2.5"},{"groupId":"OG002","lowerLimit":"-24.4","upperLimit":"42.1","value":"15.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"B cells; C3D1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-39.7","upperLimit":"15.2","value":"-30.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"NK cells; C1D8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-49.2","upperLimit":"55.3","value":"-25.8"},{"groupId":"OG001","lowerLimit":"-1.1","upperLimit":"59.6","value":"31.0"},{"groupId":"OG002","lowerLimit":"14.3","upperLimit":"56.8","value":"32.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"NK cells; C2D1"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"-28.1","upperLimit":"75.9","value":"7.4"},{"groupId":"OG002","lowerLimit":"22.2","upperLimit":"55.6","value":"47.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"NK cells; C2D8"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"-9.6","upperLimit":"61.4","value":"25.9"},{"groupId":"OG002","lowerLimit":"-26.9","upperLimit":"77.2","value":"43.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"NK cells; C3D1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"Blood samples were collected at indicated timepoints for flow cytometry assessment. Cycle (C) and Day (D). Data collected for the flow cytometry analysis from the participants enrolled in both the dose finding and dose expansion phase were analyzed in the context of the dosing regimen received, to determine any potential differences in the immune response based on the durvalumab dose.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants from cohort SARCOMA and STO, who were administered durvalumab 30 mg/kg IV in combination with tremelimumab 1 mg/kg IV in Cycles 1-4 every 28 days. From Cycle 5, onwards participants were administered durvalumab 30 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever occurred first.","id":"OG000","title":"Dose Expansion: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg"},{"description":"Participants who weighed \\>= 35 kg in Arm A and \\< 35 kg in Arm B were administered durvalumab 20 mg/kg IV in Cycle 1 followed by durvalumab in combination with tremelimumab 1 mg/kg IV in Cycles 2-5 every 28 days. From Cycle 6, onwards participants were administered durvalumab 20 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever occurred first.","id":"OG001","title":"Dose Finding: Durvalumab 20 mg/kg + Tremelimumab 1mg/kg"},{"description":"Participants who weighed \\>= 35 kg in Arm A and \\< 35 kg in Arm B were administered durvalumab 30 mg/kg IV in Cycle 1 followed by durvalumab in combination with tremelimumab 1 mg/kg IV for Cycles 2-5 every 28 days. From Cycle 6, onwards participants were administered durvalumab 20 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever occurred first.","id":"OG002","title":"Dose Finding: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg"}],"paramType":"MEDIAN","populationDescription":"Participants who received the Durvalumab + tremelimumab combination who had a pre-treatment sample collected on Day 1 and a repeat sample on Day 8 were included. As the weight of the participant was not believed to impact the immune response, it was determined that aggregating the data by dosing regimen rather than by weight group, was considered acceptable for this particular analysis.","reportingStatus":"POSTED","timeFrame":"Pre-dose Cycle 1 Day 8, pre-dose Cycle 2 Day 1, Cycle 2 Day 8, pre-dose Cycle 3 Day 1 (Dose-finding); Pre-dose Cycle 1 Day 1, Cycle 1 Day 8, pre-dose Cycle 2 Day 1 (Dose-expansion)","title":"Median Percent Change From Baseline of Cluster of Differentiation 4+ (CD4+), CD8+, B Cells, Natural Killer (NK) Cells, and T-cell Activation With Ki67","type":"SECONDARY","unitOfMeasure":"percentage of cells per cubic millimeter"}